Compare AMRX & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRX | CPB |
|---|---|---|
| Founded | 2002 | 1869 |
| Country | United States | United States |
| Employees | N/A | 13500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.8B |
| IPO Year | 2018 | 1994 |
| Metric | AMRX | CPB |
|---|---|---|
| Price | $19.82 | $19.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 18 |
| Target Price | $15.60 | ★ $26.06 |
| AVG Volume (30 Days) | 2.0M | ★ 7.6M |
| Earning Date | 05-01-2026 | 06-01-2026 |
| Dividend Yield | N/A | ★ 7.63% |
| EPS Growth | ★ 157.89 | N/A |
| EPS | 0.37 | ★ 1.31 |
| Revenue | N/A | ★ $9,744,000,000.00 |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $7.13 | $0.11 |
| P/E Ratio | $53.53 | ★ $12.81 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.56 | $19.56 |
| 52 Week High | $21.18 | $32.22 |
| Indicator | AMRX | CPB |
|---|---|---|
| Relative Strength Index (RSI) | 64.19 | 28.97 |
| Support Level | $16.59 | N/A |
| Resistance Level | N/A | $21.31 |
| Average True Range (ATR) | 0.87 | 0.67 |
| MACD | 0.26 | -0.20 |
| Stochastic Oscillator | 70.42 | 4.01 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2026 (July year-end), meals and beverages accounted for 61% of its revenue, while snacks accounted for 39%. Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.